Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenedrive Regulatory News (GDR)

Share Price Information for Genedrive (GDR)

Share Price is delayed by 15 minutes
Get Live Data
1.275    0.025 (2.04%)
Bid:
1.20
Ask:
1.35
Spread: 0.15 (12.50%)
Market Cap: £20.07m
GDR Live PriceLast checked at - London Stock Exchange

Intraday Genedrive Share Chart

Total Voting Rights

1 Apr 2021 07:00

RNS Number : 1755U
Genedrive PLC
01 April 2021
Β 

Β 

Β 

genedrive plc

("genedrive" or the "Company")

Β 

Β 

Β 

Total Voting Rights

Β 

Genedrive plc (AIM: GDR)Β notifies the market that as at 31 March 2021 the Company's issued share capital comprisesΒ 63,320,048Β ordinary shares with voting rights ('Shares'). No Shares are held in Treasury. As such, the number of Shares with voting rights isΒ 63,320,048.

Β 

This figure may be used by shareholders (and others with notifiable obligations) as their denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules.

Β 

Β 

genedrive plc

+44 (0)161 989 0245

David Budd: CEO / Matthew Fowler: CFO

Peel Hunt LLP (Nominated Adviser and Joint Broker)

+44 (0)20 7418 8900

James Steel / Victoria Erskine

finnCap (Joint Broker)

+44 (0)20 7220 0500

Geoff Nash / Kate Bannatyne / Alice Lane

Walbrook PR Ltd (Media & Investor Relations)

+44 (0)20 7933 8780 or genedrive@walbrookpr.com

Paul McManus / Anna Dunphy

+44 (0)7980 541 893 / +44 (0)7876 741 001

Β 

Β 

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
TVRDKDBKQBKDPNN
Date   Source Headline
2nd Jun 202312:25 pmRNSEquity Prepayment Facility drawdown
31st May 20237:00 amRNSBlock Listing Returns
19th May 20237:00 amRNSNICE recommends CYP2C19 genotyping
15th May 20235:56 pmRNSBlock Listing Application to AIM
11th May 202311:58 amRNSResult of General Meeting
24th Apr 202311:54 amRNSPublication of Circular and Notice of GM
11th Apr 20235:44 pmRNSHolding(s) in Company
6th Apr 20238:00 amRNSTotal Voting Rights
31st Mar 20236:32 pmRNS£5 million Equity Prepayment Facility
31st Mar 20236:32 pmRNSHalf-year Report
30th Mar 20234:35 pmRNSPrice Monitoring Extension
30th Mar 20239:05 amRNSSecond Price Monitoring Extn
30th Mar 20239:00 amRNSPrice Monitoring Extension
30th Mar 20237:00 amRNSPositive final recommendation by NICE
23rd Mar 20234:35 pmRNSPrice Monitoring Extension
20th Mar 20237:00 amRNSCommence of roll out in Greater Manchester
9th Feb 20232:05 pmRNSSecond Price Monitoring Extn
9th Feb 20232:00 pmRNSPrice Monitoring Extension
9th Feb 20239:05 amRNSSecond Price Monitoring Extn
9th Feb 20239:00 amRNSPrice Monitoring Extension
9th Feb 20237:00 amRNSAIHL test preliminary recommendation by NICE
27th Jan 20232:05 pmRNSSecond Price Monitoring Extn
27th Jan 20232:00 pmRNSPrice Monitoring Extension
26th Jan 20234:40 pmRNSSecond Price Monitoring Extn
26th Jan 20234:35 pmRNSPrice Monitoring Extension
26th Jan 20232:05 pmRNSSecond Price Monitoring Extn
26th Jan 20232:00 pmRNSPrice Monitoring Extension
25th Jan 20234:40 pmRNSSecond Price Monitoring Extn
25th Jan 20234:35 pmRNSPrice Monitoring Extension
19th Jan 20234:40 pmRNSSecond Price Monitoring Extn
19th Jan 20234:35 pmRNSPrice Monitoring Extension
29th Dec 20226:10 pmRNSResult of AGM
5th Dec 20227:00 amRNSNotice of AGM
30th Nov 20227:00 amRNSBlock Listing Six Monthly Return
21st Nov 20227:00 amRNSAudited Final Results
14th Nov 20227:00 amRNSNotice of Results
24th Oct 20227:00 amRNSGrant of options
5th Oct 20224:40 pmRNSSecond Price Monitoring Extn
5th Oct 20224:35 pmRNSPrice Monitoring Extension
5th Oct 20227:00 amRNSUS FDA pre-submission for Genedrive MT-RNR1 kit
26th Sep 20227:00 amRNSNICE to accelerate evaluation of Genedrive test
22nd Aug 20227:00 amRNSNICE includes CYP2C19-ID Kit in new programme
5th Jul 20222:06 pmRNSSecond Price Monitoring Extn
5th Jul 20222:00 pmRNSPrice Monitoring Extension
16th Jun 20227:00 amRNSNICE to evaluate the Genedrive® MT-RNR1 Test
30th May 20229:05 amRNSSecond Price Monitoring Extn
30th May 20229:00 amRNSPrice Monitoring Extension
30th May 20227:00 amRNSPoint-of-Care COV19-ID Kit receives CTDA approval
27th May 20227:00 amRNSBlock listing Interim Review
25th Apr 20229:05 amRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.